These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 25937244)

  • 41. A case of bilateral rheumatoid pleuritis successfully treated with tocilizumab.
    Ohtsuka K; Takeuchi K; Matsushita M; Aramaki T
    Mod Rheumatol; 2014 Nov; 24(6):1001-4. PubMed ID: 24533552
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis.
    Soini EJ; Hallinen TA; Puolakka K; Vihervaara V; Kauppi MJ
    J Med Econ; 2012; 15(2):340-51. PubMed ID: 22168785
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Achieving tight control in rheumatoid arthritis.
    van Hulst LT; Hulscher ME; van Riel PL
    Rheumatology (Oxford); 2011 Oct; 50(10):1729-31. PubMed ID: 21933791
    [No Abstract]   [Full Text] [Related]  

  • 44. Is there a sex bias in prescribing anti-tumour necrosis factor medications to patients with rheumatoid arthritis? A nation-wide cross-sectional study.
    Arkema EV; Neovius M; Joelsson JK; Simard JF; van Vollenhoven RF
    Ann Rheum Dis; 2012 Jul; 71(7):1203-6. PubMed ID: 22504565
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sustained clinical remission and rate of relapse after tocilizumab withdrawal in patients with rheumatoid arthritis.
    Aguilar-Lozano L; Castillo-Ortiz JD; Vargas-Serafin C; Morales-Torres J; Sanchez-Ortiz A; Sandoval-Castro C; Padilla-Ibarra J; Hernandez-Cuevas C; Ramos-Remus C
    J Rheumatol; 2013 Jul; 40(7):1069-73. PubMed ID: 23729804
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Power Doppler ultrasonographic monitoring of response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis.
    Naredo E; Möller I; Cruz A; Carmona L; Garrido J
    Arthritis Rheum; 2008 Aug; 58(8):2248-56. PubMed ID: 18668537
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel joint selection methods can reduce sample size for rheumatoid arthritis clinical trials with ultrasound endpoints.
    Allen JC; Thumboo J; Lye WK; Conaghan PG; Chew LC; Tan YK
    Int J Rheum Dis; 2018 Mar; 21(3):693-698. PubMed ID: 28971583
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate.
    Genovese MC; Lee E; Satterwhite J; Veenhuizen M; Disch D; Berclaz PY; Myers S; Sides G; Benichou O
    Ann Rheum Dis; 2013 Sep; 72(9):1453-60. PubMed ID: 23599435
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adalimumab arrests bone loss in the spine and hip of active rheumatoid arthritis patients with osteopenia.
    Li H; Liu R; Chi S; Lu Z; Yang L
    Clin Exp Rheumatol; 2015; 33(1):134-5. PubMed ID: 25536341
    [No Abstract]   [Full Text] [Related]  

  • 50. Additional use of tacrolimus after switching to tocilizumab therapy in patients with primary lack of efficacy of infliximab therapy for rheumatoid arthritis.
    Mori S
    Mod Rheumatol; 2012 Nov; 22(6):947-50. PubMed ID: 22350573
    [No Abstract]   [Full Text] [Related]  

  • 51. American College of Rheumatology/European League Against Rheumatism remission criteria for rheumatoid arthritis maintain reliable performance when evaluated in 44 joints.
    Kaneko Y; Kondo H; Takeuchi T
    J Rheumatol; 2013 Aug; 40(8):1254-8. PubMed ID: 23772077
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression.
    Brown AK; Quinn MA; Karim Z; Conaghan PG; Peterfy CG; Hensor E; Wakefield RJ; O'Connor PJ; Emery P
    Arthritis Rheum; 2006 Dec; 54(12):3761-73. PubMed ID: 17133543
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Adalimumab in advanced and early rheumatoid arthritis].
    Szekanecz Z
    Orv Hetil; 2009 Jul; 150(28):1333-4. PubMed ID: 19581162
    [No Abstract]   [Full Text] [Related]  

  • 54. Comparison of low-field dedicated extremity magnetic resonance imaging with articular ultrasonography in patients with rheumatoid arthritis.
    Horikoshi M; Suzuki T; Sugihara M; Kondo Y; Tsuboi H; Uehara T; Hama M; Takase K; Ohno S; Ishigatsubo Y; Yoshida Y; Sagawa A; Ikeda K; Ota T; Matsumoto I; Ito S; Sumida T
    Mod Rheumatol; 2010 Dec; 20(6):556-60. PubMed ID: 20524026
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis.
    Shimamoto K; Ito T; Ozaki Y; Amuro H; Tanaka A; Nishizawa T; Son Y; Inaba M; Nomura S
    J Rheumatol; 2013 Jul; 40(7):1074-81. PubMed ID: 23637318
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice.
    Bykerk VP; Östör AJ; Alvaro-Gracia J; Pavelka K; Román Ivorra JA; Graninger W; Bensen W; Nurmohamed MT; Krause A; Bernasconi C; Aassi M; Sibilia J
    Clin Rheumatol; 2015 Mar; 34(3):563-71. PubMed ID: 25604316
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study.
    Gomez-Reino JJ; Maneiro JR; Ruiz J; Roselló R; Sanmarti R; Romero AB;
    Ann Rheum Dis; 2012 Nov; 71(11):1861-4. PubMed ID: 22736086
    [TBL] [Abstract][Full Text] [Related]  

  • 58. New biologics for rheumatoid arthritis.
    Choy E
    J R Coll Physicians Edinb; 2011 Sep; 41(3):234-7. PubMed ID: 21949922
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study.
    Yazici Y; Curtis JR; Ince A; Baraf H; Malamet RL; Teng LL; Kavanaugh A
    Ann Rheum Dis; 2012 Feb; 71(2):198-205. PubMed ID: 21949007
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Longitudinal power Doppler ultrasonographic assessment of joint inflammatory activity in early rheumatoid arthritis: predictive value in disease activity and radiologic progression.
    Naredo E; Collado P; Cruz A; Palop MJ; Cabero F; Richi P; Carmona L; Crespo M
    Arthritis Rheum; 2007 Feb; 57(1):116-24. PubMed ID: 17266071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.